Abstract
Industrial-scale mammalian cell culture processes have been contaminated by viruses during the culturing phase. Although the historical frequency of such events has been quite low, the impact of contamination can be significant for the manufacturing company and for the supply of the product to patients. This chapter discusses sources of adventitious agent contamination risk in a cell culture process, provides a semiquantitative assessment of such risks, and describes potential process barriers that can be used to reduce contamination risk. High-temperature, short-time (HTST) heat treatment is recommended as the process barrier of choice, when compatible with the process. A case study assessing the compatibility of HTST heat treatment with a cell culture medium is presented, and lessons learned are shared from our experiences over many years of developing and implementing virus barriers in mammalian cell culture processes.
References
CBER (1997) Points to consider in the manufacture and testing of monoclonal antibody products for human use. J Immunother 20(3):214–243
Knipe D, Howley P (2013) Fields virology. Lippincott Williams & Wilkins, Philadelphia
Kiss R (2011) Practicing safe cell culture: applied process designs for minimizing virus contamination risk. PDA J Pharm Sci Technol 66:715–729
FDA (1998) International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin (ICH Q5A). Fed Reg 63(185):51074–51084.
EMEA/CPMP/BWP/268/95/3AB8A (1996) Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses
Kerr A, Nims R (2010) Adventitious viruses detected in biopharmaceutical bulk harvest samples over a 10 year period. PDA J Pharm Sci Technol 64:481–485
Bethencourt V (2009) Virus stalls Genzyme plant. Nat Biotechnol 27:681
Chen J (2012) Case study: a novel bacterial contamination in cell culture production - Leptospira licerasiae. PDA J Pharm Sci Technol 66:580–591
Garnick R (1996) Experience with viral contamination in cell culture. Dev Biol Stand 88:49–56
Nims R (2011) Adventitious viral contamination of biopharmaceuticals: who is at risk? BioProcess J 10:4–10
Oehmig A, Buttner M, Weiland F, Werz W, Bergemann K, Pfaff E (2003) Identification of a calicivirus isolate of unknown origin. J Gen Virol 84:2837–2845
Taleb NN (2007) The Black Swan the impact of the highly improbable. Random House, New York
Miesegaes G, Lute S, Aranha H, Brorson K (2010) Virus retentive filters. In: Flickinger M (ed) Encyclopedia of industrial biotechnology: bioprocess, bioseparation, and cell technology. Wiley, pp 1–11
Ruppach H (2014) Log10 reduction factors in viral clearance studies. BioProcess J:24–30
Ge S (2014) Virus aerosol survivability, transmission, and sampling in an environmental chamber. Dissertation
Boschetti N, Wyss K, Mischler A, Hostettler T, Kempf C (2003) Stability of minute virus of mice against temperature and sodium hydroxide. Biologicals 31:181–185
Boschetti N, Niederhauser I, Kempf C, Stuhler A, Lower J, Blumel J (2004) Different suscepibility of B19 virus and mice minute virus to low pH treatment. Transfusion 44:1079–1086
Sofer G, Lister D, Boose J (2003) Part 6, inactivation methods grouped by virus. BioPharm Int 6:S37–S42
Harris R, Coleman P, Morahan P (1974) Stability of minute virus of mice to chemical and physical agents. Appl Microbiol 28:351–354
Murphy M, Quesada GM, Chen D (2011) Effectiveness of mouse minute virus inactivation by high temperature short time treatment technology: a statistical assessment. Biologicals 39:438–443
Schleh M, Romanowski P, Bhebe P, Zhang L, Chinniah S, Lawrence B, Bashiri H, Gaduh A, Rajurs V, Rasmussen B, Chuck A, Dehghani H (2009) Susceptibility of mouse minute virus to inactivation by heat in two cell culture media types. Biotechnol Prog 25:854–860
Nims R, Gauvin G, Plavsic M (2011) Gamma irradiation of animal sera for inactivation of viruses and mollicutes - a review. Biologicals 39:370–377
Yen S, Sokolenko S, Manocha B, Blondeel E, Aucoin M, Patras A, Daynouri-Pancino F, Sasges M (2014) Treating cell culture media with UV irradiation against adventitious agents: minimal impact on CHO performance. Biotechnol Prog 30:1190–1195
Chevrefils G, Caron E, Wright H (2006) UV dose required to achieve incremental log inactivation of bacteria, protozoa, and viruses. IUVA News 8:38–45
EMA (2012, 05 25) Press release: European Medicines Agency confirms positive benefit-risk balance of MabThera
Pohlscheidt M, Charaniya S, Kulenovic F, Corrales M, Shiratori M, Bourret J, Meier S, Fallon E, Kiss R (2014) Implementing high-temperature short-time media treatment in commercial-scale cell culture manufacturing processes. Appl Microbiol Biotechnol 98:2965–2971
Cao X, Stimpfl G, Wen ZQ, Frank G, Hunter G (2013) Identification and root cause analysis of cell culture media precipitates in the viral deactivation treatment with high-temperature/short-time method. PDA J Pharm Sci Technol 67:63–73
Shiratori M, Kiss R, Prashad H, Iverson R, Bourret J, Kim M, Charaniya S (2012) Patent No. US 20130344570 A1. USA
Kuroda K, Okido M (2012) Hydroxyapatite coating of titanium implants using hydroprocessing and evaluation of their osteoconductivity. Bioinorganic Chem Appl 2012:2–7
Hauser H, Wagner R (2014) Animal cell biotechnology in biologics production. De Gruyter, Berlin
Luo J, Zhang J, Ren D, Tsai W, Li F, Amanullah A, Hudson T (2012) Probing of C-terminal lysine variation in a recombinant monoclonal antibody production using Chinese hamster ovary cells with chemically defined media. Biotechnol Bioeng 109:2306–2315
Vijayasankaran N, Varma S, Yang Y, Mun M, Arevalo S, Gawlitzek M, Swartz T, Lim A, Li F, Zhang B, Meier S, Kiss R (2013) Effect of cell culture medium components on color of formulated monoclonal antibody drug substance. Biotechnol Prog 29:1270–1277
Acknowledgments
We acknowledge many individuals too numerous to specifically name who, over the course of many years since the initial decision to develop and implement additional virus barriers, have contributed significant time and effort to ensuring success. It has truly taken a village.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Shiratori, M., Kiss, R. (2017). Risk Mitigation in Preventing Adventitious Agent Contamination of Mammalian Cell Cultures. In: Kiss, B., Gottschalk, U., Pohlscheidt, M. (eds) New Bioprocessing Strategies: Development and Manufacturing of Recombinant Antibodies and Proteins. Advances in Biochemical Engineering/Biotechnology, vol 165. Springer, Cham. https://doi.org/10.1007/10_2017_38
Download citation
DOI: https://doi.org/10.1007/10_2017_38
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-97108-7
Online ISBN: 978-3-319-97110-0
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)